“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live…
Articles by admin
Promedior recently announced the initiation of a Phase 2 trial of PRM-151, an experimental anti-fibrotic agent, in patients with Idiopathic…
Mutations in telomere genes may cause pulmonary fibrosis, emphysema and impact life expectancy, according to new research results. Telomeres are found…
A leader in plant-based biotechnology, iBio, Inc. announced a key new U.S. patent, called “Yersinia pestis Antigens, Vaccine Compositions and…
Pulmonary fibrosis may run in the family, based on the frequent occurrence of this disorder in people who are related,…
Researchers in Ann Arbor Michigan and at Cornell University in New York have found that specific types…
A new study provides improved understanding of the challenges faced by people with Idiopathic Pulmonary Fibrosis (IPF) and their…
Scientists from Japan have found that blood levels of the surfactant protein SP-D could be a good biomarker for…
Scientists in Iran have found that the lipid-lowering agent atorvastatin may reduce pulmonary injury and fibrosis caused by paraquat–a…
Boehringer Ingelheim recently announced European Union (EU) approval of nintedanib (brand name OFEV®) for idiopathic pulmonary fibrosis (IPF) treatment.